ALAM027

ALAM027 is a synthetic derivative of tetrahydrocannabinolic acid (THCA) being investigated for the treatment of pancreatic cancer. In preclinical studies, ALAM027 has shown the ability to inhibit the growth of human pancreatic cancer cell lines, including PANC-1 and AsPC-1, in vitro. In vivo research using PANC-1 xenograft mouse models demonstrated that oral administration of ALAM027 significantly reduces tumor volume and weight without causing significant toxicity or weight loss in the subjects. The compound is part of a series of novel cannabinoids designed to target pancreatic ductal adenocarcinoma, showing a tumor growth inhibition of approximately 1.6 to 2 times in animal models. It is characterized by its affinity for cannabinoid receptors, particularly CB2.